Nkarta Therapeutics Stock

nkartatx.comHealthcareFounded: 2015Funding to Date: $125MM

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.

Register for Details

For more details on financing and valuation for Nkarta Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Nkarta Therapeutics.

Register Today


Management Team

Paul Hastings
Founder, Chief Executive Officer & Board Member
Matthew Plunkett Ph.D
Chief Financial Officer and Senior Vice President
Dario Campana MD
Scientific Founder
Kanya Rajangam Ph.D
Chief Medical Officer and Senior Vice President
James Trager Ph.D
Senior Vice President and Chief Scientific Officer

Board Members

Jill Carroll
SR One
Michael Dybbs Ph.D
Samsara BioCapital
Fouad Azzam Ph.D
Life Sciences Partners
Paul Hastings
Ali Behbahani MD
New Enterprise Associates
Tiba Aynechi Ph.D
Novo Holdings

Other companies like Nkarta Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development - read this article along with other careers information, tips and advice on BioSpace
Nkarta Therapeutics announced it has raised $114 million in Series B funding led by new investor Samsara BioCapital.